Next-generation pipeline for treating mast cell driven diseases
Drug Discovery World
APRIL 6, 2023
Granular Therapeutics has now commenced proof-of-concept (POC) and IND-enabling studies as it prepares for clinical development. Since starting work on these concepts in 2019 with backing from Medicxi, Granular Therapeutics has studied the biology of mast cells and their role in chronic inflammatory diseases.
Let's personalize your content